基于门急诊患者美敏伪麻口服溶液和复方磷酸可待因口服溶液的药物利用评价  

Drug utilization evaluation of compound pseudoephedrine hydrochloride and codeine phosphate oral solution in outpatients and emergency patients

作　　者：程静茹 马丹华[2] 郝卓璐 陈新羽 焦灵利[2] 李明[2] 于丹丹[2] 唐少文[1] CHENG Jing-ru;MA Dan-hua;HAO Zhuo-lu;CHEN Xin-yu;JIAO Ling-li;LI Ming;YU Dan-dan;TANG Shao-wen(School of Public Health,Nanjing Medical University,Nanjing 211166,China;Center for ADR Monitoring of Jiangsu,Nanjing 210002,China)

机构地区：[1]南京医科大学公共卫生学院,南京211166 [2]江苏省药品不良反应监测中心,南京210002

出　　处：《中国药物依赖性杂志》2024年第3期262-266,共5页Chinese Journal of Drug Dependence

基　　金：江苏省药品监督管理局科研计划课题(202008)。

摘　　要：目的了解门急诊患者美敏伪麻口服溶液和复方磷酸可待因口服溶液的使用现状,为含麻精药品复方制剂的滥用监测提供依据。方法基于南京医科大学大数据平台检索处方两种药品的患者信息,采用用药频度(defined daily dose sum,DDDs)和药物利用指数(drug utilization index,DUI)描述,运用SPSS 26.0对不同组间构成比进行χ^(2)检验。结果获得处方美敏伪麻口服溶液的患者7964例(男女比为1∶1.29),诊断主要为呼吸道感染;处方复方磷酸可待因口服溶液的患者410例(男女比为1∶1.07),诊断主要为肺癌。美敏伪麻口服溶液2019年DDDs最高,2017—2022年DUI值均低于1,用药基本合理;复方磷酸可待因口服溶液2018年DDDs最高,且2019年、2020年DUI值分别为1.82、1.11,表明存在滥用可能。结论医疗机构应该重视复方磷酸可待因口服溶液的合理使用和潜在滥用问题,加强这类药品的监管。Objective To understand the drug utilization status of compound pseudoephedrine hydrochloride and codeine phosphate oral solution in outpatients and emergency patients,and provide evidence for the abuse monitoring.Methods Based on the big-data platform of Nanjing Medical University,the information of patients prescribed these two drugs was retrieved,and described by defined daily dose sum(DDDs)and drug utilization index(DUI).Differences of categorical variables between groups were analyzed usingχ^(2) test between with SPSS 26.0.Results 7964 patients(male to female ratio:1:1.29)were prescribed compound pseudoephedrine hydrochloride oral solution,and the corresponding diagnosis was mainly respiratory tract infection;410 patients were prescribed compound codeine phosphate oral solution(male to female ratio:1:1.07),and the corresponding diagnosis was mainly lung cancer.The DDDs of compound pseudoephedrine hydrochloride oral solution were the highest in 2019,the DUI in 2017-2022 were all lower than 1,and the medication was basically reasonable.The DDDs of compound codeine phosphate oral solution were the highest in 2018,and the DUI in 2019 and 2020 were 1.82 and 1.11,respectively,which suggested possible abuse.Conclusion Medical institutions should pay attention to the rational use and potential abuse of compound codeine phosphate oral solution,and strengthen the supervision of such drugs.

关 键 词：美敏伪麻口服溶液 复方磷酸可待因口服溶液 药物滥用 药物利用评价 

分 类 号：R749[医药卫生—神经病学与精神病学]